Course: Geographic Accessibility of COVID-19 Test to Treat Sites by Race, Ethnicity, Age, and Rurality
CME Credits: 1.00
Released: 2022-11-09
Nirmatrelvir-ritonavir and molnupiravir are oral antivirals that reduce risk of hospitalization for people with mild to moderate COVID-19. Timely access to treatment is a priority because these medications are indicated within 5 days of symptom onset. In March 2022, the Biden Administration announced the Test to Treat initiative to designate one-stop locations where people can receive a COVID-19 test, speak with a clinician, obtain an antiviral prescription, and fill the prescription for free. However, concerns remain that the Test to Treat program may not be accessible for minoritized and high-risk populations.- To explore geographic disparities in antiviral access, we quantified the accessibility of Test to Treat sites for subpopulations by race, ethnicity, age, and rurality.
Educational Objective
To identify the key insights or developments described in this article
View Full Course